CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
ID: 341905Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $350K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341905

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity under the Countermeasures Against Chemical Threats (CounterACT) initiative, aimed at supporting the early-stage development of therapeutics to mitigate the adverse health effects of toxic chemical exposure. This initiative seeks applications for projects that validate therapeutic targets and characterize lead compounds, ultimately delivering a well-characterized therapeutic candidate that improves upon existing standards of care for chemical exposure treatment. The funding is particularly relevant in the context of potential mass casualty situations involving chemical threats, as identified by the Department of Homeland Security. Interested applicants can apply for a cooperative agreement with an award ceiling of $350,000, and the application deadline is set for October 17, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-209-Full-Announcement.html
    PAR-22-209.html
    The Department of Health and Human Services has issued a Funding Opportunity Announcement (FOA) under the Countermeasures Against Chemical Threats (CounterACT) initiative, focusing on the early-stage development of therapeutics to address toxic chemical exposure effects. The NIH's National Institute of Neurological Disorders and Stroke (NINDS) and other affiliated institutes will support projects that aim to develop medical countermeasures (MCMs) applicable in mass casualty situations involving chemical threats identified by the Department of Homeland Security. The UG3/UH3 cooperative agreement mechanism allows research teams to validate therapeutic targets, optimize candidate compounds, and demonstrate efficacy, all while adhering to regulatory and biosafety guidelines. Applications must demonstrate strong preliminary data supporting their approaches, detail annual milestones for project progress, and ensure safety compliance while working with hazardous chemicals. The total project period can extend up to five years, with specific budgetary limits for each phase, necessitating careful planning for scientific rigor and institutional collaboration. Successful projects are expected to deliver a characterized therapeutic candidate that improves upon existing standards of care for chemical exposure treatment.
    Similar Opportunities
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) program, focusing on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The objective is to elucidate mechanisms of toxicity, identify biological markers, and develop potential therapeutic countermeasures for civilian populations exposed to these chemicals. This funding opportunity is critical for enhancing public safety against chemical threats, with a total of $2 million available for up to four awards, each with a maximum annual budget of $300,000 over three years. Interested applicants must submit their proposals by September 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Chemical Countermeasures Research Program (CCRP) to support basic research on the deleterious effects of acute exposure to ultra-potent synthetic (UPS) opioids. This initiative aims to identify and validate mechanisms, signaling pathways, and therapeutic targets to understand and mitigate the toxic effects and long-term health consequences associated with UPS opioid overdoses, particularly focusing on respiratory depression and related complications. With a total funding allocation of $2.5 million for fiscal year 2023, the NIH plans to fund up to six applications, emphasizing innovative collaborative research approaches to address critical public health challenges posed by synthetic opioids. Interested applicants must submit their proposals by November 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 grant titled "Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development," aimed at supporting exploratory research projects focused on radiation exposure and its medical countermeasures. The initiative seeks innovative proposals that address the development of biodosimetry techniques, medical countermeasures for radiation injuries, and animal model development, with an emphasis on high-risk, high-reward research that can enhance public health emergency preparedness. The total funding available is approximately $2 million, with individual awards capped at $100,000 per year for a maximum of two years. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)" aimed at supporting early-stage translational research for developing therapeutic agents targeting heart, lung, blood, and sleep disorders. This initiative seeks to identify lead compound series and bridge the gap between basic science discoveries and preclinical testing, emphasizing innovation through novel therapeutic approaches and strong biological rationale. The grant offers a maximum funding amount of $350,000 over a two-year period, with no cost-sharing requirement, and applications are due by December 20, 2024. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html.
    Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants," aimed at fostering community-engaged research to identify and mitigate health risks associated with environmental exposures. This initiative encourages multidisciplinary projects that actively involve community members in defining research questions and methodologies, with the goal of developing actionable public health plans based on research findings. The program is particularly focused on addressing health disparities and promoting environmental health justice, with a maximum funding amount of $500,000 available for direct costs over a period of up to five years. Interested applicants can find more information and apply by visiting the provided link or contacting the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by September 7, 2025.
    Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)." This initiative aims to provide early-stage translational support for identifying and characterizing therapeutic candidates targeting heart, lung, blood, and sleep disorders, facilitating innovative projects that address critical therapeutic gaps. The program operates under a phased grant structure, with funding capped at $350,000 per year, and requires applicants to submit detailed project management plans and measurable milestones. Interested applicants must submit their proposals electronically through Grants.gov by December 20, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" aimed at supporting collaborative research projects that address the long-term adverse effects of cancer therapies. The initiative seeks to identify and characterize the mechanisms behind therapy-induced adverse sequelae, with a focus on developing therapeutic strategies to prevent or mitigate these chronic comorbidities. This funding opportunity is crucial for enhancing patient quality of life through effective interventions based on mechanistic insights and clinical findings. Interested applicants, including various educational and community organizations, must submit their proposals by November 5, 2024, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.